elan corp narrower loss is posted on higher revenue gain elan corp posted a narrower fourth quarter net loss helped by higher revenue and a gain and said its multiple sclerosis drug tysabri will return it to profitability the irish drug makers net loss narrowed to &# million from &# million a year earlier total revenue rose to &# million the company said the latest results were boosted by an improved operating performance a tax rebate and a &# million gain on an arbitration award chief financial officer shane cooke said "we are optimistic that elan will achieve break even on an adjusted earnings before interest tax depreciation and amortization basis by the end of the year " 
